Bill SponsorSen. Chris H. WilsonRepublicanFloor SponsorRep. Tyler ClancyRepublican
Current version: SB0222S02 (substitute)
Utah's "Right to Try" law allows seriously ill patients to access experimental drugs and medical devices that have passed initial FDA safety testing but haven't yet received full approval. This bill would expand that law by creating a new category called "eligible illness" — a severely debilitating or life-threatening condition where a doctor determines that conventional treatments offer no satisfactory or comparable option — so patients with serious but non-terminal conditions could also qualify for investigational treatments, provided the treatment is still undergoing an active FDA-regulated investigation. It would also broaden the definition of "terminal illness" to explicitly include cancer diagnosed by a board-certified oncologist, update the list of allowable drug forms to include any liquid formulation rather than only suspensions, and require manufacturers who provide investigational drugs or devices to Utah patients under the new "eligible illness" category to report annually to a legislative committee on how many patients were treated, what conditions were treated, and any adverse outcomes, unless those patients were already part of a formal clinical trial.
AI-generated summary, not yet reviewed by Better Utah staff.
AI summaries can make mistakes and leave things out. The bill text is the official version.
This bill amends provisions related to when a patient may obtain and use investigational drugs and devices to treat an illness.
This bill:
Introduction, completed
Jan 30
Senate Rules, completed
Feb 2
Senate committee, completed
Senate 2nd reading, completed
Feb 20 · 23 to 0 (see the votes)
Senate 3rd reading, completed
Feb 23 · 24 to 0 (see the votes)
House Rules, completed
Feb 25
House committee, completed
Feb 27 · Recommended, 10 to 0 (see the votes)
House 3rd reading, completed
Mar 5 · 67 to 0 (see the votes)
Governor signed, completed
Mar 18
Introduction, completed
Jan 30
Senate Rules, completed
Feb 2
Senate committee, completed
Senate 2nd reading, completed
Feb 20 · 23 to 0 (see the votes)
Senate 3rd reading, completed
Feb 23 · 24 to 0 (see the votes)
House Rules, completed
Feb 25
House committee, completed
Feb 27 · Recommended, 10 to 0 (see the votes)
House 3rd reading, completed
Mar 5 · 67 to 0 (see the votes)
Governor signed, completed
Mar 18
Current version: SB0222S02 (substitute)
Introduction, completed
Jan 30
Senate Rules, completed
Feb 2
Senate committee, completed
Senate 2nd reading, completed
Feb 20 · 23 to 0 (see the votes)
Senate 3rd reading, completed
Feb 23 · 24 to 0 (see the votes)
House Rules, completed
Feb 25
House committee, completed
Feb 27 · Recommended, 10 to 0 (see the votes)
House 3rd reading, completed
Mar 5 · 67 to 0 (see the votes)
Governor signed, completed
Mar 18
Introduction, completed
Jan 30
Senate Rules, completed
Feb 2
Senate committee, completed
Senate 2nd reading, completed
Feb 20 · 23 to 0 (see the votes)
Senate 3rd reading, completed
Feb 23 · 24 to 0 (see the votes)
House Rules, completed
Feb 25
House committee, completed
Feb 27 · Recommended, 10 to 0 (see the votes)
House 3rd reading, completed
Mar 5 · 67 to 0 (see the votes)
Governor signed, completed
Mar 18
Utah's "Right to Try" law allows seriously ill patients to access experimental drugs and medical devices that have passed initial FDA safety testing but haven't yet received full approval. This bill would expand that law by creating a new category called "eligible illness" — a severely debilitating or life-threatening condition where a doctor determines that conventional treatments offer no satisfactory or comparable option — so patients with serious but non-terminal conditions could also qualify for investigational treatments, provided the treatment is still undergoing an active FDA-regulated investigation. It would also broaden the definition of "terminal illness" to explicitly include cancer diagnosed by a board-certified oncologist, update the list of allowable drug forms to include any liquid formulation rather than only suspensions, and require manufacturers who provide investigational drugs or devices to Utah patients under the new "eligible illness" category to report annually to a legislative committee on how many patients were treated, what conditions were treated, and any adverse outcomes, unless those patients were already part of a formal clinical trial.
AI-generated summary, not yet reviewed by Better Utah staff.
AI summaries can make mistakes and leave things out. The bill text is the official version.
This bill amends provisions related to when a patient may obtain and use investigational drugs and devices to treat an illness.
This bill:
Loading the versions…
Motion: Favorable recommendation
PASSEDYes 3 · No 1 · Absent 3
PASSEDYes 23 · No 0 · Absent 6
PASSEDYes 24 · No 0 · Absent 5
Motion: Favorable recommendation
PASSEDYes 10 · No 0 · Absent 4
PASSEDYes 67 · No 0 · Absent 8